Chronic In Vivo Imaging of a Focal Cortical Dysplasia Mouse Model Reveals Progressive Neuronal Loss with No Senolytic or Antiseizure Efficacy Following Dasatinib–Quercetin Treatment
Preprint
Abstract
Summary: Objective: Focal cortical dysplasia (FCD) type II is a common cause of pediatric drug-resistant epilepsy with no disease-modifying treatment. It arises from somatic mutations in the mTOR pathway that produce a mosaic population of mTOR-hyperactive dysmorphic neurons (DNs) with a senescence phenotype. A recent report showed that oral dasatinib– quercetin (DQ), both putative senolytics, selectively eliminates these neurons and abolishes seizures in an Mtor p.S2215F model. However, this has not been tested in a second FCD model and neuron loss was shown only by cross-sectional histology. Methods: Using chronic cranial windows and longitudinal in vivo two-photon imaging, we tracked genetically labeled neurons over eight weeks. In a mosaic MTOR p.L2427P FCD model on a C57BL/6J background, we combined imaging with continuous video-EEG, immunohistochemistry (IHC), and LC–MS/MS pharmacokinetics in 47 mice. Seizure and pharmacokinetic sampling were extended to a smaller Swiss/CD1 cohort, the strain used previously. Results: Imaging revealed progressive loss of mTOR mut (16.7%) and non-mTOR mut (13.1%) neurons, with minimal loss in unmatched non-FCD controls. In IHC, lesions contained β-galactosidase-positive (B-Gal + ) cells, but oral DQ showed no evidence of eliminating DNs or reducing seizure frequency, duration, or burden; seizures also persisted in CD1 mice. B-Gal + cells tended to be less dense after DQ, but not significantly after correction. These data are more consistent with a senomorphic than a senolytic effect. Brain dasatinib (median 8.5 nM) exceeded its Src/ABL IC 50 , whereas quercetin (median 12 nM) was nearly two orders of magnitude below its BCL-XL affinity. Significance: Longitudinal tracking of single neurons shows progressive loss of labeled neurons in an FCD model, whereas the reported senolytic and antiseizure effects of DQ were not reproduced. DQ should not be assumed to act as a senolytic across FCD models, strains, or MTOR variants. Dependence on strain, mutation, or brain exposure bears on clinical translation. Key Points Longitudinal in vivo two-photon imaging showed progressive loss of mTOR-mutant neurons in an FCD type II mouse model Oral dasatinib–quercetin treatment did not eliminate dysmorphic neurons or reduce seizures in C57BL/6J mice; seizures persisted in CD1 mice Dasatinib–quercetin did not eliminate neurons or abolish seizures in an MTOR p.L2427P FCD model, so its efficacy may not generalizeKeywords
Funding Information
- Ministry of Health of the Czech Republic (NW24-04-00041)
- Ministry of Health of the Czech Republic (NW26-04-00517)
- Ministry of Education, Youth and Sports of the Czech Republic (EU – Next Generation EU: LX22NPO5107)
- Ministry of Education, Youth and Sports of the Czech Republic (Brain dynamics, OP JAK, CZ.02.01.01/00/22_008/0004643)
- Charles University, Prague, CZ (UNCE24/MED/021 - EXCITE)
- Charles University, Prague, CZ (PRIMUS/23/MED/011)
- Charles University, Prague, CZ (423325)
This publication has 56 references indexed in Scilit:
- Seizure occurrence in FCD type II is predicted by lesion position and linked to cytoarchitectural alterationsActa Neuropathologica Communications, 2025
- Threshold of somatic mosaicism leading to brain dysfunction with focal epilepsyBrain, 2024
- Targeting pathological cells with senolytic drugs reduces seizures in neurodevelopmental mTOR-related epilepsyNature Neuroscience, 2024
- Cortical Dysplasia in Rats Provokes Neurovascular Alterations, GLUT1 Dysfunction, and Metabolic Disturbances That Are Sustained Post-Seizure InductionMolecular Neurobiology, 2022
- Sirolimus for epileptic seizures associated with focal cortical dysplasia type IIAnnals of Clinical and Translational Neurology, 2022
- Dissecting the genetic basis of focal cortical dysplasia: a large cohort studyActa Neuropathologica, 2019
- Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading to intractable epilepsyNature Medicine, 2015
- Direct Binding of Bcl-2 Family Proteins by Quercetin Triggers Its Pro-Apoptotic ActivityACS Chemical Biology, 2014
- Direct confocal acquisition of fluorescence from X-gal staining on thick tissue sectionsScientific Reports, 2013
- Discovery of N-(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical AssaysJournal of Medicinal Chemistry, 2004